TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) — Satellos Bioscience (Nasdaq: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced the assignment of the International Nonproprietary Name (INN) “forazapadin” for the Company’s orally administered, small molecule drug candidate designed to restore muscle regeneration that was previously known as SAT-3247.
This excerpt is quoted from the original release. Read the full announcement on GlobeNewsWire.
Brief Summary
Satellos Bioscience has made a significant announcement by assigning the International Nonproprietary Name (INN) forazapadin to its leading drug candidate, formerly known as SAT-3247. This new name is a pivotal step in the drug’s journey towards market introduction.
Key highlights of this development include:
- Forazapadin aims to enhance muscle regeneration in degenerative muscle diseases.
- This designation supports the drug’s global marketing and branding efforts.
- Satellos continues to focus on life-improving treatments for patients.
- Investors can anticipate further updates as clinical trials progress.
Why it matters: The assignment of a nonproprietary name is essential for the drug’s future as it indicates readiness for broader acceptance and potential market entry.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by GlobeNewsWire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.